- Home
- MYGN vs EMD Comparison
MYGN vs EMD Comparison
Compare MYGN & EMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- EMD
- Stock Information
- Founded
- MYGN 1991
- EMD 2003
- Country
- MYGN United States
- EMD United States
- Employees
- MYGN N/A
- EMD N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EMD Finance/Investors Services
- Sector
- MYGN Health Care
- EMD Finance
- Exchange
- MYGN Nasdaq
- EMD Nasdaq
- Market Cap
- MYGN 642.0M
- EMD 604.6M
- IPO Year
- MYGN 1995
- EMD N/A
- Fundamental
- Price
- MYGN $7.40
- EMD $10.52
- Analyst Decision
- MYGN Hold
- EMD
- Analyst Count
- MYGN 13
- EMD 0
- Target Price
- MYGN $13.50
- EMD N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- EMD 248.5K
- Earning Date
- MYGN 11-06-2025
- EMD 01-01-0001
- Dividend Yield
- MYGN N/A
- EMD 10.25%
- EPS Growth
- MYGN N/A
- EMD N/A
- EPS
- MYGN N/A
- EMD N/A
- Revenue
- MYGN $832,900,000.00
- EMD N/A
- Revenue This Year
- MYGN $0.17
- EMD N/A
- Revenue Next Year
- MYGN $6.19
- EMD N/A
- P/E Ratio
- MYGN N/A
- EMD N/A
- Revenue Growth
- MYGN 3.83
- EMD N/A
- 52 Week Low
- MYGN $3.76
- EMD $7.85
- 52 Week High
- MYGN $29.30
- EMD $9.55
- Technical
- Relative Strength Index (RSI)
- MYGN 66.01
- EMD 66.17
- Support Level
- MYGN $7.13
- EMD $10.16
- Resistance Level
- MYGN $7.80
- EMD $10.49
- Average True Range (ATR)
- MYGN 0.44
- EMD 0.09
- MACD
- MYGN 0.04
- EMD 0.01
- Stochastic Oscillator
- MYGN 78.61
- EMD 86.07
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.